Safety and Efficacy of Chronic Weekly Rozanolixizumab in Generalized Myasthenia Gravis: the Randomized Open-Label Extension MG0004 Study
Journal of Neurology(2025)
Key words
Myasthenia gravis,Rozanolixizumab,FcRn inhibitor,Phase 3 clinical trial
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined